Application of SCRN1 inhibitor in preparation of medicine for treating hepatocellular carcinoma

The invention relates to the technical field of biological medicine, provides novel application of SCRN1, and particularly relates to application of an SCRN1 inhibitor in preparation of a medicine for treating hepatocellular carcinoma. The invention further provides an SCRN1 inhibitor recombinant vector and a hepatocellular carcinoma treatment pharmaceutical composition taking the SCRN1 inhibitor or a recombinant expression vector thereof as an active component. Experimental results show that the expression of SCRN1 in tumor tissues is increased, normal proliferation of liver cancer cells is not affected, but the sensitivity of the cells to sorafenib can be reduced. The SCRN1-/-tumor cell is more sensitive to sorafenib treatment, and a patient with high SCRN1 expression is more difficult to benefit from sorafenib treatment, so that the invention discloses a new application of the SCRN1 molecule in hepatocellular carcinoma treatment typing and treatment scheme selection, and a new thought and a new way are pro